htra1 genentech:Development of a therapeutic anti
Development of a therapeutic anti
由ITom著作·2020·被引用31次—Anti-HtrA1Fab15H6.v4.D221isalsocalledFHTR2163orRO7171009andwassuppliedbyGenentech.ThestudyconsistsofaSADstagewithdoses ...。其他文章還包含有:「AllostericinhibitionofHTRA1activitybyaconformational...」、「EfficacyandSafetyofAnti–HighTemperatureRequirementA1...」、「OurPipeline」、「Phase1StudyoftheAnti」
查看更多 離開網站Allosteric inhibition of HTRA1 activity by a conformational ...
https://www.ncbi.nlm.nih.gov
HTRA1 is a secreted protease composed of an N-terminal IGFBP-domain, a Kazal-like domain, a central trypsin-like serine protease domain and a C- ...
Efficacy and Safety of Anti–High Temperature Requirement A1 ...
https://medically.gene.com
Aug 24 / Roche and Genentech. Efficacy and Safety of Anti–High Temperature Requirement A1 (Anti-HTRA1) Fab in Geographic Atrophy Secondary to AMD: GAllego ...
Our Pipeline
https://www.gene.com
Our Research and Early Development pipeline has over 30 new molecular entities (NMEs) in active clinical development.
Phase 1 Study of the Anti
https://pubmed.ncbi.nlm.nih.go
FHTR2163, a novel Fab directed against HtrA1, was well tolerated with no DLTs or ... 5 Genentech, Inc., South San Francisco, CA, USA.